Glycogen reduction in myotubes of late-onset Pompe disease patients using antisense technology
Page 1 of 1
Glycogen reduction in myotubes of late-onset Pompe disease patients using antisense technology
Jon Moulton Thu Jun 08, 2017 2:43 pm
Goina E, Peruzzo P, Bembi B, Dardis A, Buratti E. Glycogen reduction in myotubes of late-onset Pompe disease patients using antisense technology. Mol Ther. 2017;[Epub ahead of print] doi:10.1016/j.ymthe.2017.05.019
Jon Moulton- Posts : 5721
Join date : 2010-03-12
Age : 61
Location : Philomath, Oregon, USA -
Similar topics» Antisense Oligonucleotide-mediated Suppression of Muscle Glycogen Synthase 1 Synthesis as an Approach for Substrate Reduction Therapy of Pompe Disease
» From Cryptic Toward Canonical Pre-mRNA Splicing in Pompe Disease: a Pipeline for the Development of Antisense Oligonucleotides
» Antisense Oligonucleotides Promote Exon Inclusion and Correct the Common c.-32-13T>G GAA Splicing Variant in Pompe Disease
» Mutations in MAPKBP1 Cause Juvenile or Late-Onset Cilia-Independent Nephronophthisis
» Antisense PMO cocktails effectively skip dystrophin exons 45-55 in myotubes transdifferentiated from DMD patient fibroblasts
» From Cryptic Toward Canonical Pre-mRNA Splicing in Pompe Disease: a Pipeline for the Development of Antisense Oligonucleotides
» Antisense Oligonucleotides Promote Exon Inclusion and Correct the Common c.-32-13T>G GAA Splicing Variant in Pompe Disease
» Mutations in MAPKBP1 Cause Juvenile or Late-Onset Cilia-Independent Nephronophthisis
» Antisense PMO cocktails effectively skip dystrophin exons 45-55 in myotubes transdifferentiated from DMD patient fibroblasts
Page 1 of 1
Permissions in this forum:
You cannot reply to topics in this forum|
|
|